1. Home
  2. NCV vs ATYR Comparison

NCV vs ATYR Comparison

Compare NCV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCV
  • ATYR
  • Stock Information
  • Founded
  • NCV 2003
  • ATYR 2005
  • Country
  • NCV United States
  • ATYR United States
  • Employees
  • NCV N/A
  • ATYR N/A
  • Industry
  • NCV Finance Companies
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NCV Finance
  • ATYR Health Care
  • Exchange
  • NCV Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • NCV 274.5M
  • ATYR 290.6M
  • IPO Year
  • NCV N/A
  • ATYR 2015
  • Fundamental
  • Price
  • NCV $13.29
  • ATYR $3.34
  • Analyst Decision
  • NCV
  • ATYR Strong Buy
  • Analyst Count
  • NCV 0
  • ATYR 6
  • Target Price
  • NCV N/A
  • ATYR $18.60
  • AVG Volume (30 Days)
  • NCV 405.1K
  • ATYR 1.1M
  • Earning Date
  • NCV 01-01-0001
  • ATYR 05-07-2025
  • Dividend Yield
  • NCV 12.48%
  • ATYR N/A
  • EPS Growth
  • NCV N/A
  • ATYR N/A
  • EPS
  • NCV N/A
  • ATYR N/A
  • Revenue
  • NCV N/A
  • ATYR N/A
  • Revenue This Year
  • NCV N/A
  • ATYR $551.06
  • Revenue Next Year
  • NCV N/A
  • ATYR $2,144.84
  • P/E Ratio
  • NCV N/A
  • ATYR N/A
  • Revenue Growth
  • NCV N/A
  • ATYR N/A
  • 52 Week Low
  • NCV $2.84
  • ATYR $1.42
  • 52 Week High
  • NCV $3.59
  • ATYR $4.66
  • Technical
  • Relative Strength Index (RSI)
  • NCV 60.88
  • ATYR 51.21
  • Support Level
  • NCV $12.93
  • ATYR $3.06
  • Resistance Level
  • NCV $13.23
  • ATYR $3.67
  • Average True Range (ATR)
  • NCV 0.20
  • ATYR 0.25
  • MACD
  • NCV 0.08
  • ATYR 0.01
  • Stochastic Oscillator
  • NCV 91.46
  • ATYR 46.77

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: